उत्पाद विवरण
Cfara Injection serves as a purine nucleoside metabolic inhibitor, specifically designed to address acute lymphoblastic leukaemia (ALL) in pediatric patients aged 1 to 21 years. This targeted treatment option is utilized when other therapies have proven ineffective or have ceased to provide benefits. By disrupting the metabolism of purine nucleosides, Cfara Injection helps to inhibit the growth and proliferation of malignant white blood cells, thereby assisting in the management of this aggressive form of cancer. It is crucial for healthcare providers to monitor patients closely for potential side effects and to assess overall treatment response. Patients receiving Cfara Injection should be informed about the importance of adhering to follow-up appointments and lab tests to ensure optimal safety and effectiveness. As with any medication, a thorough discussion of risks and benefits with a healthcare professional is essential prior to initiation. With its focused approach, Cfara Injection represents a vital option in the ongoing fight against ALL, aiming to improve outcomes for young patients facing this challenging diagnosis.
Send Email 
जांच भेजें
जांच भेजें
एसएमएस भेजें
English
Spanish
French
German
Italian
Chinese (Simplified)
Japanese
Korean
Arabic
Portuguese